Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

• Main Authors: Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Jaranit Kaewkungwal, Peter Dawson, Jittima Dhitavat, Benjaluck Phonrat, Siriwat Akapirat, Nicos Karasavvas, Lindsay Wieczorek, Victoria Polonis, Michael A. Eller, Poonam Pegu, Dohoon Kim, Alexandra Schuetz, Surat Jongrakthaitae, Yingjun Zhou, Faruk Sinangil, Sanjay Phogat, Carlos A. Diazgranados, James Tartaglia, Elizabeth Heger, Kirsten Smith, Nelson L. Michael, Jean Louis Excler, Merlin L. Robb, Jerome H. Kim, Robert J. O'Connell, Sandhya Vasan, Arom Pitisuthitham, Yupa Sabmee, Narongrid Sirisopana, Chirapa Eamsila, Prapaporn Savaraj, Wanlaya Labwech, Siriluck Teerachia, Nuntisa Chotirosniramit, Taweewat Supindham, Boonlure Pruenglampoo, Patcharaphan Sugandhavesa, Natthapol Kosashunhanan, Oranitcha Kaewthip, Piyathida Sroysuwan, Pawinee Jarujareet, Silvia Ratto-Kim, Sebastian Molnar, Jesse Schoen, Nampueng Churikanont, Saowanit Getchalarat, Nongluck Sangnoi, Bessara Nuntapinit, Anant Phramtong, Pornsuk V. Grandin, Sirinan Madnote, Surawach Rittiroongrad, Boot Kaewboon, Rapee Trichavaroj, Jiraporn Puangkaew, Somsak Chantakulkij, Phiromrat Rakyat, Pornchanok Panjapornsuk, Nipattra Tragonlugsana, Weerawan Chuenarom, Mark de Souza, Viseth Ngauy, Nittaya Phanuphak, Nitiya Chomchey, Puttachard Saengtawan, Nipat Teeratakulpisarn, Rungsun Rerknimitr, Eugene Kroon, Carter A. Lee, Suchada Chinaworapong
• 其他作者: GlaxoSmithKline SpA
• 格式: Article
• 出版: 2020
• 主題: Immunology and Microbiology; Medicine
• 在線閱讀: https://repository.li.mahidol.ac.th/handle/123456789/54573
• 機構: Mahidol University

© 2020 Elsevier Ltd Background: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunological effect of an additional vaccine boost...